Although autotransfusion is used in a wide variety of surgical procedures, it is largely unexplored for use in oncologic operations. This study evaluates the impact of autotransfusion in hepatectomy for hepatocellular carcinoma.
Patients and Methods:
Fifty-four patients with hepatocellular carcinoma underwent hepatectomy by receiving autologous blood transfusion (group 1). Fifty patients receiving homologous blood without any autologous blood were matched for comparison (group 2).
No statistical differences were found between group 1 and group 2 patients in cumulative recurrence rates (62.8% vs 67.3%, respectively) or cumulative survival rates (61.9% vs 52.8%). Autologous transfusion reduced the mean volume of homologous blood used (814 mL vs 3466 mL). The mean postoperative hemoglobin level, platelet count, prothrombin time, and partial thromboplastin time were comparable between groups.
Autotransfusion is a safe and effective procedure in patients with hepatocellular carcinoma undergoing hepatectomy.(Arch Surg. 1993;128:1065-1069)
Fujimoto J, Okamoto E, Yamanaka N, et al. Efficacy of Autotransfusion in Hepatectomy for Hepatocellular Carcinoma. Arch Surg. 1993;128(9):1065–1069. doi:10.1001/archsurg.1993.01420210129021
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: